CAPORALI, R.; RAVASIO, R.; RAIMONDO, P.; SALAFFI, F. Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy. Global and Regional Health Technology Assessment, [S. l.], v. 8, n. 1, p. 69–79, 2021. DOI: 10.33393/grhta.2021.2267. Disponível em: https://journals.aboutscience.eu/index.php/grhta/article/view/2267. Acesso em: 23 nov. 2024.